Experimental drug PMG1015 tested for lung scarring disease
NCT ID NCT05895565
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal was to check the drug's safety and how the body processes it, not whether it works. Participants received either PMG1015 or a placebo, and researchers monitored side effects and lung function. Because this is a small, phase 1 study, results are preliminary and do not yet show if PMG1015 can treat IPF.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PMG1015 (an experimental drug)
- What this could lead to
- If safe and effective, PMG1015 could offer a new treatment option to slow lung scarring in idiopathic pulmonary fibrosis.
- What could go wrong
- This is a very early, small phase 1b safety trial with only 29 participants. It is not designed to prove the drug works, and many early-stage drugs fail in later trials. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
-
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New inhaled drug for lung disease tested in healthy people first
- New hope for lung scarring: HSK44459 enters final trial phase
- Healthy volunteers to test experimental lung disease drug
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients